Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-261 in Healthy Chinese Volunteers
NCT07535775Phase 1Active, not recruiting
- Sponsor
- SPH-BIOCAD
- Start
- May 2026
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCD-261 (3 arms), sponsored by SPH-BIOCAD. Primary endpoints: Proportion of subjects with serious adverse events at 309 days, Proportion of subjects with adverse events at 309 days and 2 more. Started May 2026; status: active, not recruiting.
02
Drugs
BCD-261
Beyond the preview
Go deeper on NCT07535775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07535775.